Company: HURA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0000950170-25-108972
Chunk: 3

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1A
Chunk 3
---
 Kineta employees, filing fees, printing and mailing expenses and other related charges.

We will also incur integration costs in connection with the Kineta Merger. There are a large number of processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the Kineta Merger and the integration of the two companies’ businesses. 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

•On June 2, 2025, the Company and the selling stockholders (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “Offering”), an aggregate of 4,759,309 shares of common stock together with warrants to purchase an equal number of shares of common stock at an exercise price of $3.3125 (the “Warrants”), for an aggregate offering amount of approximately $12.6 million. The combined effective offering price for each share and accompanying Warrant in the Offering was $2.65. The securities were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder. 

Item 3. Defaults Upon Senior Securities.

None.